New biologic (Ab-IPL-IL-17) for IL-17-mediated diseases: identification of the bioactive sequence (nIL-17) for IL-17A/F function.
Saviano, Anella Manosour, Adel Abo Raucci, Federica Merlino, Francesco Marigliano, Noemi Schettino, Anna Wahid, Mussarat Begum, Jenefa Filer, Andrew Manning, Julia E
Saviano, Anella
Manosour, Adel Abo
Raucci, Federica
Merlino, Francesco
Marigliano, Noemi
Schettino, Anna
Wahid, Mussarat
Begum, Jenefa
Filer, Andrew
Manning, Julia E
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2023-08-14
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Objectives: Interleukin (IL) 17s cytokines are key drivers of inflammation that are functionally dysregulated in several human immune-mediated inflammatory diseases (IMIDs), such as rheumatoid arthritis (RA), psoriasis and inflammatory bowel disease (IBD). Targeting these cytokines has some therapeutic benefits, but issues associated with low therapeutic efficacy and immunogenicity for subgroups of patients or IMIDs reduce their clinical use. Therefore, there is an urgent need to improve the coverage and efficacy of antibodies targeting IL-17A and/or IL-17F and IL-17A/F heterodimer.
Methods and results: Here, we initially identified a bioactive 20 amino acid IL-17A/F-derived peptide (nIL-17) that mimics the pro-inflammatory actions of the full-length proteins. Subsequently, we generated a novel anti-IL-17 neutralising monoclonal antibody (Ab-IPL-IL-17) capable of effectively reversing the pro-inflammatory, pro-migratory actions of both nIL-17 and IL-17A/F. Importantly, we demonstrated that Ab-IPL-IL-17 has less off-target effects than the current gold-standard biologic, secukinumab. Finally, we compared the therapeutic efficacy of Ab-IPL-IL-17 with reference anti-IL-17 antibodies in preclinical murine models and samples from patients with RA and IBD. We found that Ab-IPL-IL-17 could effectively reduce clinical signs of arthritis and neutralise elevated IL-17 levels in IBD patient serum.
Conclusions: Collectively, our preclinical and in vitro clinical evidence indicates high efficacy and therapeutic potency of Ab-IPL-IL-17, supporting the rationale for large-scale clinical evaluation of Ab-IPL-IL-17 in patients with IMIDs.
Keywords: arthritis, rheumatoid; autoimmune diseases; autoimmunity; inflammation.
Citation
Saviano, A., Manosour, A. A., Raucci, F., Merlino, F., Marigliano, N., Schettino, A., Wahid, M., Begum, J., Filer, A., Manning, J. E., Casillo, G. M., Piccolo, M., Ferraro, M. G., Marzano, S., Russomanno, P., Bellavita, R., Irace, C., Amato, J., Alfaifi, M., Rimmer, P., … Maione, F. (2023). New biologic (Ab-IPL-IL-17) for IL-17-mediated diseases: identification of the bioactive sequence (nIL-17) for IL-17A/F function. Annals of the rheumatic diseases, ard-2023-224479. Advance online publication. https://doi.org/10.1136/ard-2023-224479
Type
Article